Trading Summary - August 25.
16.5M traded today - as
Trading Summary - August 25.
16.5M traded today - as follows:
.0007: 2.2M
.0006: 9.5M
.0005: 4.8M
Yet more excellent news from $DIGX today - this time much bigger - a potential merger being lined up with a meeting next week.
The company is making good use of its' new Twitter account now and today also reminded the investing community of the fact that it had a gross profit of $1.1M+ in the first half of 2017.
We can now look forward to additional updates on both this merger and the implementation of the additional services being offered in the chiropractic chain offices - per the Strategic Growth Plan just announced - over the coming days, weeks and months..
Despite being issued a warning that they would lose their shares at a time of the whales" choosing, a few clueless traders failed to cancel the 15M>17M they had on the ask at .0007 - 2.2M of it was subsequently bought out.
Again, a few impatient insignificant small holders traded their shares either on an undercut ask at .0006 or were foolish enough to whack the strong whale bid at .0005. The more amateurs we get rid of before more updates flow, the thinner to the upside $DIGX will become.
The long term whales maintained a visible 40M+ bid at .0005 at the start of the day and increased it to 53M on the merger news.
Any undercut ask .0006s that appeared were snapped up almost immediately.
The long whales will continue to buy at all prices that makes sense to them at any given point to have a cache for trading on any demand led run, the Q3 and through to the Annual Report in March 2018.
$DIGX will most likely not be allowed to go to previous year-end or inter-Q lows.
In my opinion, nobody has bought $DIGX in 2017 at a price that it isn't likely to exceed in the coming months (2017 high .0013) through to the Annual Report (March 2018).
Those that fail to cancel their sell orders at .0007, .0008 and .0009 can expect to lose their shares over the coming days and weeks.
Regardless of whether iHub posters lose interest over the coming days and weeks, detailed coverage will continue here as $DIGX remains one of my top picks for repeat profits for those that are patient and trade it to best effect (keep all cheapest batches of shares - create an inventory of shares at higher prices to trade on every run - big or small).
American EcoFuels Inc (AEFI) Stock Research Links
"Per Ardua Ad Astra" - "Through Adversity To The Stars"
A very apposite motto for those who trade successfully in the OTC market..
All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...
Continue Reading
Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...
Continue Reading
Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...
Continue Reading
Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...
Continue Reading
Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....
Continue Reading
Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...
Continue Reading
Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...
Continue Reading
Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...
Continue Reading
If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
Top 5 Most Recently Viewed Articles
Canadian Stocks See Notable Gains The Canadian stock market has shown encouraging signs of growth lately, with various sectors playing a part in this upward movement. The S&P/TSX Composite Index achieved a remarkable increase of 0.57%, marking a significant point in its trading history. Key Sectors Driving Market Growth The rise in stock prices can largely be credited to...
Continue Reading
Stepping into Michigan It might not be a Wall Street headliner, but Bookmark Medical's move into Michigan sure says a lot about their growth ambitions. On August 3, 2026, the Nashville-based healthcare group wrapped up acquiring Village Medical Michigan. This is Bookmark's maiden voyage into the Great Lake State, where it's taken over the reins of seven primary care...
Continue Reading
Astrotech Corporation Reports Strong Fiscal Performance Recently, Astrotech Corporation (NASDAQ: ASTC) announced its financial results for the fiscal year that ended on June 30. The report highlights notable advancements from its subsidiary, 1st Detect, and how these developments are contributing to overall revenue and growth potential. Key Financial Highlights The...
Continue Reading
Neptune Flood Research Report Offers Insights on NFIP Transition Recent research indicates that private flood insurers may be capable of taking on 95% of policies from the NFIP, helping to mitigate federal financial exposure. Neptune Flood Research Group has published a comprehensive report analyzing the U.S. flood insurance market. The study emphasizes the challenges...
Continue Reading
Valerio Therapeutics Announces Strategic Refocus Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) has made a pivotal announcement regarding its strategic business direction. The company has decided to halt all clinical trials, including the ongoing VIO-01 trial. This decision comes in response to significant financing challenges impacting the organization. While...
Continue Reading